πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Caribou Biosciences, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines

Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.

Tags: CAR-T therapy, COVID-19, anti-viral drugs, biotechnology, infectious diseases, oncology, vaccine development

Symbol: ANIX

Recent Price: $2.50

Industry: Biotechnology

CEO: Dr. Amit Kumar Ph.D.

Sector: Healthcare

Employees: 4

Address: 3150 Almaden Expressway, San Jose, CA 95118

Phone: 408 708 9808

Last updated: 2024-12-31

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics, Inc. Common Stock logo
Market Cap: Medium
Employees: Low

CRG-022

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets resistance mechanisms in B-cell malignancies.

Tags: B-cell Malignancies, Biotechnology, CAR T-cell Therapies, Cancer Treatment, Clinical-stage

Symbol: CRGX

Recent Price: $13.76

Industry: Biotechnology

CEO: Ms. Gina Chapman

Sector: Healthcare

Employees: 150

Address: 1900 Alameda De Las Pulgas, San Mateo, null 94403

Phone: 650-379-6143

Leadership

  • Gina Chapman, President and Chief Executive Officer
  • Anup Radhakrishnan, Chief Financial Officer/Chief Business Officer
  • Ginna Laport, MD, Chief Medical Officer
  • Shishir Gadam, PhD, Chief Technical Officer
  • Michael Ports, PhD, Chief Scientific Officer
  • Kari Leetch, Chief People Officer
  • Halley Gilbert, JD, Chief Legal Officer
  • Bethany Rogers, SVP, Product Strategy and Commercialization
  • Faisal Shawwa, SVP, Finance
  • Tonia J. Buchholz, PhD, Head of Clinical Science
  • Kanika Chawla, PhD, Head of Process Sciences
  • Sandra Chen, Head of Clinical Quality and Risk Management
  • Michelle Gray, Head of Clinical Operations
  • Adam Haskett, Head of External Manufacturing
  • David Hoffman, JD, Head of Intellectual Property & Transactions
  • Anissa Irwin, Head of Quality Assurance and Systems
  • Brett Masterson, Head of Marketing
  • Rob McCombie, Head of CMC Regulatory
  • Frank McDonald, Head of Clinical Data Management
  • Priya Parameswaran, Head of Corporate Strategy and Business Operations
  • Shabnum Patel, PHD, Head of MSAT
  • Mary Rodley, Head of CMC Strategy and Operations
  • Abhijeet Sarvaiya, Head of Statistical Programming
  • Brian Schoelkopf, Head of FP&A
  • Christophe Suchet, Head of IT
  • Beth Vasievich, PhD, Head of Commercial Planning and Operations
  • Jun Wang, Head of Procurement
  • John Orwin, Chairman of the Board
  • Abraham Bassan, Board Director
  • Kapil Dhingra, M.B.B.S, Board Director
  • Reid Huber, PHD, Board Director
  • David Lubner, Board Director
  • Krishnan Viswanadhan, Pharm.D, Board Director
  • Jane Pritchett Henderson, Board Director

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

Mustang Bio, Inc.

Mustang Bio, Inc. logo
Market Cap: Lowest
Employees: Low

Gene and CAR T Cell Therapies

Mustang Bio, Inc. is a biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. It focuses on developing gene therapy programs and CAR T cell therapies, including treatments for X-linked severe combined immunodeficiency and various types of cancer.

Tags: CAR T cell, biopharmaceutical, gene therapy, genetic diseases, hematologic cancers, solid tumors

Symbol: MBIO

Recent Price: $0.19

Industry: Biotechnology

CEO: Dr. Manuel Litchman M.D.

Sector: Healthcare

Employees: 80

Address: 377 Plantation Street, Worcester, MA 01605

Phone: 781 652 4500

Leadership

  • Manuel Litchman, M.D., President, Chief Executive Officer and Director
  • Greg Furrow, M.S., FRQA, Chief Quality Officer
  • James Murphy, B.A., Ad interim Chief Financial Officer
  • Michael S. Weiss, Chairman of the Board of Directors
  • Lindsay A. Rosenwald, M.D., Director
  • Adam J. Chill, Director
  • Neil Herskowitz, Director
  • Michael J. Zelefsky, M.D., Director
  • Mustang Bio, Inc., Company

Last updated: 2024-12-31

Arcellx, Inc.

Arcellx, Inc. logo
Market Cap: High
Employees: Low

CART-dd BCMA

Arcellx, Inc. is a clinical-stage biotechnology company dedicated to developing immunotherapies for cancer and other incurable diseases, with a focus on its lead product candidate, CART-dd BCMA, for treating relapsed or refractory multiple myeloma.

Tags: acute myeloid leukemia, biotechnology, cancer treatment, clinical-stage, immunotherapy, multiple myeloma, myelodysplastic syndrome

Symbol: ACLX

Recent Price: $78.35

Industry: Biotechnology

CEO: Mr. Rami Elghandour

Sector: Healthcare

Employees: 130

Address: 25 West Watkins Mill Road, Gaithersburg, MD 20878

Phone: 240 327 0603

Last updated: 2024-12-31

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

UCART19

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Tags: CAR T cell, allogeneic T cell therapies, cancer treatment, clinical trials, immuno-oncology

Symbol: ALLO

Recent Price: $2.10

Industry: Biotechnology

CEO: Dr. David D. Chang M.D., Ph.D.

Sector: Healthcare

Employees: 232

Address: 210 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 457 2700

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Cabaletta Bio, Inc.

Cabaletta Bio, Inc. logo
Market Cap: Low
Employees: Low

DSG3-CAART

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its leading product, DSG3-CAART, is in Phase I trials for treating mucosal pemphigus vulgaris.

Tags: CAAR T cells, T cell therapies, autoimmune diseases, biotechnology, clinical trials

Symbol: CABA

Recent Price: $2.24

Industry: Biotechnology

CEO: Dr. Steven A. Nichtberger M.D.

Sector: Healthcare

Employees: 136

Address: 2929 Arch Street, Philadelphia, PA 19104

Phone: 267 759 3100

Leadership

  • Steven Nichtberger, M.D., President, Chief Executive Officer, and Co-Founder
  • Samik Basu, M.D., Chief Scientific Officer
  • Gwendolyn Binder, Ph.D., President, Science & Technology
  • David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer
  • Arun Das, M.D., Chief Business Officer
  • Michael Gerard, General Counsel
  • Heather Harte-Hall, Chief Compliance Officer
  • Anup Marda, Chief Financial Officer
  • Martha O’Connor, Chief Human Resources Officer
  • Sarah Yuan, Ph.D., Chief Technology Officer
  • Catherine Bollard, M.D., Independent Director, George Washington University
  • Scott Brun, M.D., Independent Director, formerly at AbbVie
  • Richard Henriques, M.B.A., Independent Director, former CFO of Gates Foundation, former Controller at Merck
  • Mark Simon, M.B.A., Independent Director, Torreya Partners
  • Shawn Tomasello, M.B.A., Independent Director, former CCO of Kite Pharma, Inc.

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Cue Biopharma, Inc.

Cue Biopharma, Inc. logo
Market Cap: Low
Employees: Lowest

CUE-101

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing biologic drugs to modulate the human immune system for treating cancers, chronic infectious diseases, and autoimmune disorders.

Tags: autoimmune disorders, biopharmaceutical, cancer, chronic diseases, immune system

Symbol: CUE

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Daniel R. Passeri J.D., M.Sc.

Sector: Healthcare

Employees: 53

Address: 21 Erie Street, Cambridge, MA 02139

Phone: 617 949 2680

Leadership

  • Dan Passeri, Chief Executive Officer
  • Anish Suri, President and Chief Scientific Officer
  • Lucinda Warren, Chief Business Officer
  • Matteo Levisetti, Chief Medical Officer
  • Kerri-Ann Millar, Chief Financial Officer
  • Colin Sandercock, Senior Vice President and General Counsel
  • Frank Morich, M.D., Ph.D., Chairman of the Board
  • Dan Passeri, M.Sc., J.D., Chief Executive Officer
  • Peter Kiener, D.Phil.,
  • Fred Driscoll,
  • Patrick Verheyen,
  • Pamela D. Garzone, Ph.D.,

Last updated: 2024-12-31

Precision BioSciences, Inc.

Precision BioSciences, Inc. logo
Market Cap: Lowest
Employees: Low

ARCUS

Precision Bio Sciences, Inc. is a clinical stage gene editing company specializing in in vivo gene editing and ex vivo allogeneic CAR T therapies, including the ARCUS genome editing platform and various investigational CAR T immunotherapies.

Tags: CAR T therapies, allogeneic CAR T, clinical stage, gene editing, genetic disorders, immunotherapy

Symbol: DTIL

Recent Price: $4.26

Industry: Biotechnology

CEO: Mr. Michael Amoroso

Sector: Healthcare

Employees: 109

Address: 302 East Pettigrew Street, Durham, NC 27701

Phone: 919 314 5512

Last updated: 2024-12-31

Gossamer Bio, Inc.

Gossamer Bio, Inc. logo
Market Cap: Low
Employees: Low

GB002, GB004, GB5121, GB7208

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.

Tags: biopharmaceutical, central nervous system lymphoma, immunology, inflammation, inflammatory bowel disease, multiple sclerosis, oncology, pulmonary arterial hypertension, therapeutics

Symbol: GOSS

Recent Price: $0.88

Industry: Biotechnology

CEO: Mr. Faheem Hasnain

Sector: Healthcare

Employees: 135

Address: 3013 Science Park Road, San Diego, CA 92121

Phone: 858 684 1300

Leadership

  • Faheem Hasnain, Chairman
  • Richard Aranda, M.D., Chief Medical Officer
  • Jeff Boerneke, General Counsel and Secretary
  • Matt Cravets, Senior Vice President, Biometrics
  • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
  • Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
  • Caryn Peterson, Executive Vice President, Regulatory Affairs
  • Bob Smith, Chief Commercial Officer
  • Christian Waage, Executive Vice President, Technical Operations & Administration
  • Deanna Weber, Senior Vice President, Human Resources
  • Russell J. Cox, Director
  • Thomas Daniel, Director
  • Skye Drynan, Director
  • Sandra Milligan, Director
  • Steven D. Nathan, Director
  • John Quisel, Director

Last updated: 2024-12-31

LogicBio Therapeutics, Inc.

LogicBio Therapeutics, Inc. logo
Market Cap: Low
Employees: Medium

LB-001

Logic Bio Therapeutics, Inc. is a genetic medicine company focused on genome editing and gene therapy treatments using its Gene Ride and s AAVy platforms. Its lead product candidate, LB-001, is in clinical trials for methylmalonic acidemia.

Tags: Gene Ride, LB-001, gene therapy, genetic medicine, genome editing, methylmalonic acidemia, s AAVy

Symbol: LOGC

Recent Price: $7.08

Industry: Biotechnology

CEO: Mr. Rishi Bajaj

Sector: Healthcare

Employees: 452

Address: 65 Hayden Ave, 2Nd Floor, Lexington, MASSACHUSETTS 02421

Phone: 16172450399

Last updated: 2024-12-31

Renovaro Biosciences Inc.

Renovaro Biosciences Inc. logo
Market Cap: Lowest
Employees: Lowest

RENB-HV-01, RENB-HV-12, RENB-HB-01, RENB-DC-11, RENB-DC-12-XX, RENB-HV-21

Renovaro Biosciences Inc. is a pre-clinical stage biotechnology company focused on R&D of pharmaceutical and biological products for treating HIV, HBV, and cancer in the U.S. The company has a robust product pipeline and strategic partnerships, and was formerly known as Enochian Biosciences, Inc.

Tags: HBV treatment, HIV treatment, biotechnology, cancer treatment, pharmaceutical research, strategic partnerships

Symbol: RENB

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. David H. Weinstein

Sector: Healthcare

Employees: 25

Address: 2080 Century Park East, Los Angeles, CA 90067

Phone: 305 918 1980

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31